FDA approves Myfortic® to prevent organ rejection after kidney transplantation

 | Source: Novartis Pharma AG Novartis Pharma AG

FDA approves Myfortic® to prevent organ rejection after kidney transplantation

 
Basel, 1 March 2004 - Novartis Pharma AG announced today that the U.S. Food and Drug Administration has approved the use of Myfortic® (mycophenolic acid) delayed release tablets in combination with cyclosporine and corticosteroids to prevent organ rejection in kidney transplant patients.
 
Please see full press release under the following link:

Attachments

Press release
GlobeNewswire

Recommended Reading